Journal · Updated 2026-08-11
Hims & Hers GLP-1 Review 2026: The Post-Settlement, Brand-Only Storefront, Priced All-In
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Hims & Hers exited compounded GLP-1s for new patients with its March 9, 2026 settlement with Novo Nordisk; the current storefront is brand-only: Wegovy at two ninety-nine, oral Wegovy at two forty-nine, Zepbound at three ninety-nine — each atop the one forty-nine monthly membership, making the true all-ins roughly four forty-eight, three ninety-eight, and five forty-eight. The comparison that governs every line: the manufacturers' own channels sell the same products at three forty-nine (pen), one forty-nine (oral), and two ninety-nine-to-four forty-nine (vials) with no membership — so the Hims math only closes if the medication line's discount plus the platform's service value exceeds one forty-nine a month, every month.
The membership math, line by line
Injectable Wegovy: two ninety-nine plus one forty-nine equals four forty-eight against NovoCare's three forty-nine — a ninety-nine-dollar monthly premium for the platform (and NovoCare's one ninety-nine two-fill introduction widens it early). Oral: two forty-nine plus one forty-nine equals three ninety-eight against NovoCare's one forty-nine-to-one ninety-nine — the widest gap on the menu. Zepbound: three ninety-nine plus one forty-nine equals five forty-eight against LillyDirect's four forty-nine ceiling — and against two ninety-nine/three ninety-nine during titration, with the 45-day rule the only string. What the one forty-nine buys — a slick app, provider access, the convenience of one storefront — is real but generic; what it doesn't buy is a price edge anywhere on the board, and the 2026 ledger records how the storefront got here.
Verdict
Post-settlement Hims is a brand reseller with a subscription, and the review reduces to whether its platform is worth a hundred-to-two-hundred-fifty monthly over the makers' own counters — for most buyers, no, and the direct channels (plus the $25 insured path Hims can also help navigate — worth asking) are the rational defaults. The fit that remains: existing Hims subscribers already paying the membership for other care, for whom the marginal math changes; everyone else should price nexthealth — the direct channel — first, because in 2026 the manufacturers decided to compete on price, and resellers haven't caught up.
Questions people ask
Does Hims still sell compounded semaglutide?
Not to new patients: the March 9, 2026 settlement with Novo Nordisk ended its compounded GLP-1 offering. The current storefront is brand-only — Wegovy, oral Wegovy, and Zepbound — atop the $149 membership.
How much do GLP-1s really cost at Hims & Hers?
All-in with the mandatory $149 membership: about $448/month for Wegovy ($299 + $149), $398 for oral Wegovy, and $548 for Zepbound — versus $349, $149–$199, and $299–$449 at NovoCare and LillyDirect directly, with no membership.
Is Hims worth it for brand GLP-1s?
Only if the platform's convenience is worth $99–$249/month over the manufacturers' own channels — a hard case for medication shoppers. Existing members already paying $149 for other care have better marginal math; everyone else should price NovoCare/LillyDirect first and ask any platform to run insurance before paying cash.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.